APA (7th ed.) Citation

A, R., E, C., LA, H., PD, B., TA, B., L, E., . . . L, P. (2024). Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 42(22), 2632. https://doi.org/10.1200/JCO.23.02614

Chicago Style (17th ed.) Citation

A, Ríos-Hoyo, Cobain E, Huppert LA, Beitsch PD, Buchholz TA, Esserman L, van 't Veer LJ, Rugo HS, and Pusztai L. "Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 42, no. 22 (2024): 2632. https://doi.org/10.1200/JCO.23.02614.

MLA (9th ed.) Citation

A, Ríos-Hoyo, et al. "Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 42, no. 22, 2024, p. 2632, https://doi.org/10.1200/JCO.23.02614.